NCT05494944

Low Power ThULEP for Prostate Size More Than 80 gm

Completed NA Last updated 12 August 2022

What this trial tests

NA trial testing ThuLEP in Benign Prostatic Hyperplasia in 40 participants. Completed in 30 March 2022.

Timeline

1 December 2019

Primary endpoint
30 March 2022

30 March 2022

Quick facts

Lead sponsor	Kasr El Aini Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 December 2019
Primary completion	30 March 2022
Estimated completion	30 March 2022
Sites	1 location across Egypt

Drugs / interventions tested

• ThuLEP

Conditions studied

• Benign Prostatic Hyperplasia — all drugs for Benign Prostatic Hyperplasia →

Sponsor

Kasr El Aini Hospital

Who can join

Eligibility, male only, with Benign Prostatic Hyperplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Feasibility and Efficacy of lower power thulium enucleation of prostate more than 80 grams

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Surgical outcomes of low-power thulium laser enucleation of prostates >80 g. One-year of follow-up.
   Morsy S, Kamal I, Meshref A, Abdel-Mohsen M, et al · · 2023 · cited 4× · PMID 38045774 · DOI 10.5173/ceju.2023.50